Eupraxia Pharmaceuticals Inc. (EPRX.TO)

CAD 4.59

(-2.34%)

Long Term Debt Summary of Eupraxia Pharmaceuticals Inc.

  • Eupraxia Pharmaceuticals Inc.'s latest annual long term debt in 2023 was - CAD , down -100.0% from previous year.
  • Eupraxia Pharmaceuticals Inc.'s latest quarterly long term debt in 2024 Q1 was - CAD , down 0.0% from previous quarter.
  • Eupraxia Pharmaceuticals Inc. reported annual long term debt of 10.36 Million CAD in 2022, up 10.3% from previous year.
  • Eupraxia Pharmaceuticals Inc. reported annual long term debt of 9.4 Million CAD in 2021, up 4632.26% from previous year.
  • Eupraxia Pharmaceuticals Inc. reported quarterly long term debt of 34.95 Thousand CAD for 2024 Q2, down 0.0% from previous quarter.
  • Eupraxia Pharmaceuticals Inc. reported quarterly long term debt of - CAD for 2023 Q4, down -100.0% from previous quarter.

Annual Long Term Debt Chart of Eupraxia Pharmaceuticals Inc. (2023 - 2017)

Historical Annual Long Term Debt of Eupraxia Pharmaceuticals Inc. (2023 - 2017)

Year Long Term Debt Long Term Debt Growth
2023 - CAD -100.0%
2022 10.36 Million CAD 10.3%
2021 9.4 Million CAD 4632.26%
2020 198.66 Thousand CAD -20.91%
2019 251.19 Thousand CAD 0.0%
2018 - CAD -100.0%
2017 5132.00 CAD 0.0%

Peer Long Term Debt Comparison of Eupraxia Pharmaceuticals Inc.

Name Long Term Debt Long Term Debt Difference
Appili Therapeutics Inc. 875.2 Thousand CAD 100.0%
Helix BioPharma Corp. - CAD NaN%
Microbix Biosystems Inc. 6.37 Million CAD 100.0%
Medicenna Therapeutics Corp. - CAD NaN%
Satellos Bioscience Inc. - CAD NaN%
Oncolytics Biotech Inc. 290 Thousand CAD 100.0%
Sernova Corp. - CAD NaN%